Ibogaine Treatment
The Science
Ibogaine allows for increased pathways and connections between neuro- receptors in the brain that typically are not aligned. Connecting these pathways allows for communication between neuro- receptors.
Ibogaine helps activate serotonin receptors in the brain. Serotonin is the key hormone that stabilizes our mood, feelings of wellbeing, and happiness. It enables brain cells to communicate with each other. Balancing serotonin levels helps to reduce depression, anxiety, and helps regulate sleep.
Ibogaine increases activity in the visual cortext of the brain which processes visual information. This process allows our perceptions in life to become more keen and acute. It decreases part of the brain responsible for our inner sense of ego.
Ibogaine has the ability to reset the Default Mode Network (DMN) in the brain. The reset in the neurochemistry will dramatically reduce anxiety, mood disorders, and depression. It helps balance the neurochemistry of the brain.
We participate in our own collection of data, research and clinical findings so we can play a part in the global research on Ibogaine. Our goal is to help as many people as possible in a safe, therapeutic environment and to help them achieve life changing results. Our Ibogaine clinic and Ibogaine treatment is highly rated world wide.
Therapy Sessions and After Care Planning
Individual Therapeutic Sessions
Pre and Post Psychotherapy sessions.
Customized to clients needs to get to the core life issues and past traumas. We offer Treatment preparation so our clients feel confident and comfortable before, during, and after their treatment.
Post Treatment Aftercare and planning
We have a number of options for clients customized individually to their needs. We want to make sure the transition to home is healthy. This process is discussed at clients arrival to center and throughout their stay. This is part of our Ibogaine treatment program.
Oceanside in-house research study on methamphetamine use
Clinical research study on methamphetamine use with positive outcomes
Oceanside Treatment Center Nassau, Bahamas
A Prospective Longitudinal Observational Study on Clinical Ibogaine Treatment for Methamphetamine Use Disorder
1. Introduction
Methamphetamine use disorder is a significant and escalating public health challenge due to the drug's high potential for addiction and neurotoxicity. In response to the need for more effective treatment strategies, this study was conducted at Oceanside Treatment Center in Nassau, Bahamas, to evaluate the outcomes of Clinical Ibogaine Treatment in individuals with methamphetamine dependence. The primary goal was to assess abstinence at 3, 6, and 12 months post-treatment among clients who completed the full protocol and engaged in structured aftercare.
2. Study Design
Study Type: Prospective Longitudinal Observational Study
Location: Oceanside Treatment Center, Nassau, Bahamas
Study Duration: 12 months (March 24, 2023 - March 22, 2024)
Sample Size: 24 clients
Inclusion Criteria:
- Diagnosed with methamphetamine use disorder
- Daily use of methamphetamine between 0.5g and 2g
- Duration of use from 1 to 6 years
- Adults aged 18 and over
3. Participant Demographics
Total Participants: 24
Gender Breakdown:
- Male: 14 (58.3%)
- Female: 6 (41.7%)
Use History:
- Daily methamphetamine use ranged from 0.5 grams to 2 grams
- Duration of abuse ranged from 1 to 6 years
4. Treatment Protocol
Participants completed a 8-day inpatient treatment protocol consisting of the following components:
Days 1-5 (Pre-treatment Transition Phase):
- Medical assessment and stabilization
- Nutritional support and detox preparation
- Psychosocial counseling and integration
Day 6 (Ibogaine Administration):
- Clinical Ibogaine dose administered under full-time medical supervision
Days 7-8 (Post-treatment Monitoring):
- Observation, rest, and discharge planning
5. Aftercare Program
Following treatment, all clients participated in a structured aftercare counseling program, designed to reinforce the therapeutic effects of Ibogaine and support long-term abstinence.
Months 1-6: Two counseling sessions per week
Months 7-12: One counseling session per week
Participation Rate: 60% of participants engaged consistently in aftercare throughout the 12-month follow-up period
6. Outcome Measures
Primary Outcome: Abstinence from methamphetamine use at 3, 6, and 12 months post-treatment.
Time Point | Clients Abstinent | Percentage (n = 24)
-------------- |-------------------|---------------------
3 Months | 22 | 92%
6 Months | 20 | 83%
12 Months | 18 | 75%
Abstinence was determined through self-reporting, clinical observation, and follow-up assessments conducted during aftercare.
7. Observations
- Participants demonstrated a strong initial response to Ibogaine therapy, with a 92% abstinence rate at 3 months.
- Sustained abstinence at 6 months (83%) and 12 months (75%) indicates promising long-term efficacy.
- Continued engagement in counseling and support services appeared to positively influence recovery outcomes.
- The structured 8-day program, combined with consistent follow-up care, provided a comprehensive and effective framework for recovery from methamphetamine use disorder.
8. Conclusion
This prospective observational study provides evidence that Clinical Ibogaine Treatment, when delivered in a medically supervised and structured environment, can result in high rates of abstinence from methamphetamine use. The integration of aftercare support played a critical role in sustaining recovery, with strong outcomes observed at 3, 6, and 12 months post-treatment.
• 3 Months: 22 of 24 clients abstinent (92%)
• 6 Months: 20 of 24 clients abstinent (83%)
• 12 Months: 18 of 24 clients abstinent (75%)
